Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis

• Published in: Psychopharmacology Vol. 237; no. 4; pp. 1121 - 1130
• Main Authors: Appiah-Kusi, E., Petros, N., Wilson, R., Colizzi, M., Bossong, M. G., Valmaggia, L., Mondelli, V., McGuire, P., Bhattacharyya, S.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2020; Springer; Springer Nature B.V
• Subjects: Adolescent; Adult; Anti-Anxiety Agents - administration & dosage; Antianxiety agents; Antipsychotic Agents - administration & dosage; Antipsychotics; Anxiety; Anxiety - blood; Anxiety - drug therapy; Anxiety - psychology; Biomedical and Life Sciences; Biomedicine; Cannabidiol; Cannabidiol - administration & dosage; Cannabinoids; Corticosteroids; Double-Blind Method; Female; Hormones; Humans; Hydrocortisone - blood; Male; Neurosciences; Original Investigation; Patients; Pharmacology/Toxicology; Psychiatry; Psychosis; Psychotic Disorders - blood; Psychotic Disorders - drug therapy; Psychotic Disorders - psychology; Risk Factors; Social Behavior; Social interactions; Speech - drug effects; Speech - physiology; Stress, Psychological - blood; Stress, Psychological - drug therapy; Stress, Psychological - psychology; Treatment Outcome; Variance analysis; Young Adult; United Kingdom; Psychosis; Cannabidiol; Trier Social Stress Test; Ultra-high risk

Rationale Stress is a risk factor for psychosis and treatments which mitigate its harmful effects are needed. Cannabidiol (CBD) has antipsychotic and anxiolytic effects. Objectives We investigated whether CBD would normalise the neuroendocrine and anxiety responses to stress in clinical high risk fo...